MiniMed Group (NASDAQ:MMED) Research Coverage Started at Morgan Stanley

Morgan Stanley began coverage on shares of MiniMed Group (NASDAQ:MMED) in a research note released on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $19.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. BTIG Research assumed coverage on shares of MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $25.00 price target for the company. Bank of America started coverage on shares of MiniMed Group in a report on Tuesday. They issued a “buy” rating and a $27.00 price objective on the stock. Wall Street Zen raised shares of MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Mizuho began coverage on shares of MiniMed Group in a research report on Tuesday. They set an “outperform” rating and a $21.00 target price for the company. Finally, Piper Sandler assumed coverage on MiniMed Group in a research note on Tuesday. They issued a “neutral” rating and a $16.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.45.

MiniMed Group Stock Down 3.2%

Shares of MMED stock opened at $14.01 on Tuesday. MiniMed Group has a 12 month low of $13.52 and a 12 month high of $20.48.

Key MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.